Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Biotech company Oxford Biomedica increased its revenue in the first half of 2020 by 6%, it announced this morning.
Bioprocessing and commercial development were particularly strong, posting revenues of £23.4m, up by 24%.
The company recorded an operating loss of £5.8m for the first six months of the year, down from £6.1m in the first half of 2019.
After a fundraising round, the group now has more than £50m in cash on its balance sheet.
CEO John Dawson highlighted Oxford Biometrica's work with AstraZeneca, with which it has signed a three-year deal for large-scale manufacturing of a potential vaccine for COVID-19.